Abstract:Triple-negative breast cancer (TNBC) has a high degree of malignancy, lack of effective diagnosis and treatment, and poor prognosis. Bioinformatics methods are used to screen the hub genes and signal pathways involved in the progress of TNBC to provide reliable biomarkers for the diagnosis and treatment of TNBC. Download the raw data of four TNBC-related datasets from the Gene Expression Omnibus (GEO) database and use them for bioinformatics analysis. GEO2R tool was used to analyze and identify differentially expressed (DE) mRNAs. DAVID database was used to carry out gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genome Pathways (KEGG) signal pathway enrichment analysis for DE mRNAs. STRING database and Cytoscape were used to build DE mRNAs protein-protein interaction (PPI) network diagram and visualize PPI network, respectively. Through cytoHubba, cBioPortal database, Kaplan-Meier mapper database, Gene Expression Profiling Interactive Analysis (GEPIA) Database, UALCAN Database, The Cancer Genome Atlas (TCGA) database, Tumor Immunity Estimation Resource identify hub genes. Perform qRT-PCR, Human Protein Atlas analysis, mutation analysis, survival analysis, clinical-pathological characteristics, and infiltrating immune cell analysis. 22 DE mRNAs were identified from the four datasets, including 16 upregulated DE mRNAs and six downregulated DE mRNAs. Enrichment analysis of the KEGG showed that DE mRNAs were principally enriched in pathways in cancer, mismatch repair, cell cycle, platinum drug resistance, breast cancer. Six hub genes were screened based on the PPI network diagram of DE mRNAs. Survival analysis found that TOP2A, CCNA2, PCNA, MSH2, CDK6 are related to the prognosis of TNBC. In addition, mutations, clinical indicators, and immune infiltration analysis show that these five hub genes play an important role in the progress of TNBC and immune monitoring. Compared with MCF-10A, MCF-7, and SKBR-3 cells, TOP2A, PCNA, MSH2, and CDK6 were significantly upregulated in MDA-MB-321 cells. Compared with normal, luminal, and Her-2 positive tissues, CCNA2, MSH2, and CDK6 were significantly upregulated in TNBC. Through comparative analysis of GEO datasets related to colorectal cancer and lung adenocarcinoma, it was determined that these five hub genes were unique differentially expressed genes of TNBC. At last, the hub genes related to the progression, prognosis, and immunity of TNBC have been successfully screened. They are indeed specific to TNBC as prognostic features. They can be used as potential markers for the prognosis of TNBC and provide potential therapeutic targets.

Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data

Identification Of Potential Oncogenes In Triple-Negative Breast Cancer Based On Bioinformatics Analyses

Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis

Identification of a Group of Therapeutic Targets and Prognostic Biomarker for Triple Negative Breast Cancer

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC

Identification of Potential Key Genes and Pathways Predicting Pathogenesis and Prognosis for Triple-Negative Breast Cancer

Identification of Novel Prognostic Genes of Triple-Negative Breast Cancer Using Meta-Analysis and Weighted Gene Co-Expressed Network Analysis.

Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer

Correction To: Identification of a Five Genes Prognosis Signature for Triple-Negative Breast Cancer Using Multi-Omics Methods and Bioinformatics Analysis

Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

Predicting the Prognosis and Immunotherapeutic Response of Triple-Negative Breast Cancer by Constructing a Prognostic Model Based on CD8+ T Cell-Related Immune Genes.

A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer

A Prognostic Model of Genetic Markers for Triple-Negative Breast Cancer Based on Machine Learning and Bioinformatics Analysis.

Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer

Integrated Analysis of Expression Profiling Data Identifies Three Genes in Correlation with Poor Prognosis of Triple-Negative Breast Cancer

Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies

A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer

Exploring a novel four-gene system as a diagnostic and prognostic biomarker for triple-negative breast cancer, using clinical variables

Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer

Construction of a prognostic model for triple‐negative breast cancer based on immune‐related genes, and associations between the tumor immune microenvironment and immunological therapy